Burazer L, Milovanovic K, Milovanovic M, Vuckovic O, Velickovic T C, Gavrovic-Jankulovic M
Department of Allergy, Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia.
Med Vet Entomol. 2011 Mar;25(1):77-83. doi: 10.1111/j.1365-2915.2010.00906.x. Epub 2010 Sep 6.
House dust mite (HDM) allergy has different clinical and immunological patterns in different geographic regions. The impact of raw material of commercial Dermatophadoides pteronyssinus (Acari: Pyroglyphidae) mite bodies on the quality of allergen extracts for allergy diagnosis in the Serbian population has not been previously evaluated. House dust mite bodies obtained from manufacturers in Europe, South America and Australia were used in the preparation of allergen extracts for in vivo diagnosis and serological analysis in a group of 14 HDM-allergic adults. In the group of mite-allergic patients, there was no statistically significant difference in skin test reactivity (Wilcoxon matched pairs test) among the three HDM body extract preparations. In a CAP inhibition assay, two extracts (A and C) achieved maximum inhibition of >90%, whereas extract B demonstrated a different inhibition slope and lower inhibition potential (80%). However, a remarkable difference in immunoglobulin E reactivity using Western blot analysis with individual patients' sera was observed in one of the preparations (extract B). These findings emphasize the need for the careful selection of starting material for the preparation of HDM diagnostic reagents intended for use in patients from geographically distinct regions as these preparations can have implications on the selection criteria for patient-tailored immunotherapy of HDM allergy.
屋尘螨(HDM)过敏在不同地理区域具有不同的临床和免疫模式。此前尚未评估过商业性粉尘螨(螨亚纲:尘螨科)螨体原料对塞尔维亚人群过敏诊断用变应原提取物质量的影响。从欧洲、南美洲和澳大利亚的制造商处获取的屋尘螨螨体用于制备变应原提取物,对一组14名对HDM过敏的成年人进行体内诊断和血清学分析。在螨过敏患者组中,三种HDM螨体提取物制剂之间的皮肤试验反应性无统计学显著差异(Wilcoxon配对检验)。在CAP抑制试验中,两种提取物(A和C)达到了>90%的最大抑制率,而提取物B表现出不同的抑制斜率和较低的抑制潜力(80%)。然而,在其中一种制剂(提取物B)中,使用个体患者血清进行蛋白质印迹分析时,观察到免疫球蛋白E反应性存在显著差异。这些发现强调,对于为来自地理上不同区域的患者制备HDM诊断试剂而言,需要谨慎选择起始原料,因为这些制剂可能会影响HDM过敏患者个体化免疫治疗的选择标准。